Publications by authors named "Stephane Dalle"

Claim this Profile
I
Integrated histomolecular approach to discriminate primary cutaneous follicle centre and marginal zone lymphoma of the scalp.
Marie Donzel, Alexis Trecourt, Stéphane Dalle, Olivier Harou, Marie Perier-Muzet

Pathology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five and 10-year evolution of longitudinal melanonychia appearing before the age of 5: A multicenter prospective cohort study from the International Dermoscopy Society.
Félix K Pham, Bengü Nisa Akay, Philippe Bahadoran, Cristina Carrera, Linda K Martin, Stéphane Dalle

J Am Acad Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International real-world study of combination immunotherapy sequences in metastatic melanoma.
Mora Guardamagna, Sarah E Lochrin, James William Smithy, Michael Postow, Caroline Gaudy-Marqueste, Stéphane Dalle

J Immunother Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed panniculitis post cytoreductive surgery and intraperitoneal chemotherapy with mitomycin C.
Emmanuel Ribereau-Gayon, Olivier Harou, Stéphane Dalle, Claire Theillac, Bénédicte Reynaud

J Eur Acad Dermatol Venereol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana M Arance, Stéphane Dalle

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, Luis de la Cruz Merino, Eduardo Castañón Álvarez, Stephane Dalle

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, Luis de la Cruz Merino, Eduardo Castañón Álvarez, Stephane Dalle

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.
Emily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, Miguel Angel Berciano-Guerrero, Maria Del Carmen Álamo de la Gala, Stéphane Dalle

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.
Adèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Jean-Baptiste Mear, Stéphane Dalle

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Sylvie Negrier, Stephane Dalle

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of dermoscopic signs of regression in melanocytic lesions with immune checkpoint inhibitor response in metastatic melanoma patients.
Samy Belkaïd, Marion Clerc, Mona Amini-Adle, Delphine Maucort-Boulch, Stéphane Dalle

J Eur Acad Dermatol Venereol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of cutaneous squamous cell carcinomas in patients with Sézary syndrome: A nationwide multicenter retrospective study.
Louise Guillon, Caroline Ram-Wolff, Serge Boulinguez, Marie Beylot-Barry, Michel D'Incan, Stéphane Dalle

J Am Acad Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, Dirk Schadendorf, Paolo A Ascierto, Stephane Dalle

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the anti-C-C chemokine receptor type 4 monoclonal antibody mogamulizumab in patients with advanced cutaneous T-cell lymphomas and with large cell transformation.
Lou Faltot, Marie Donzel, Georgio Chidiac, Brigitte Balme, Nicolas Romain-Scelle, Stéphane Dalle

Br J Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF or BRAF mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
Caroline Robert, Michal Kicinski, Caroline Dutriaux, Émilie Routier, Anne-Sophie Govaerts, Stéphane Dalle

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.
Karine Billard, Laurent Mortier, Olivier Dereure, Sophie Dalac, Henri Montaudié, Stephane Dalle

Br J Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, Dirk Schadendorf, Paolo A Ascierto, Stéphane Dalle

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Sylvie Negrier, Stephane Dalle

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients.
Fanny Beltzung, Marie Beylot-Barry, Maxime Battistella, Caroline Ram-Wolff, Adèle de Masson, Stéphane Dalle

Histopathology· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma.
Elisa Gobbini, Margaux Hubert, Anne-Claire Doffin, Anais Eberhardt, Léo Hermet, Stephane Dalle

Cancer Immunol Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma.
Chloé Wirbel, Simon Durand, Félix Boivin, Maud Plaschka, Valentin Benboubker, Stéphane Dalle

Cancer Immunol Immunother· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Cohort of Patients With Resected High-Risk Melanoma Treated by Adjuvant Anti-PD1 Therapy.
Liza Benzoni, Anaïs Eberhardt, Sarah Milley, Safa Idoudi, Camille Trefcon, Stéphane Dalle

Cancer Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Acute kidney injury in cancer patients receiving immune checkpoint inhibitor therapy-shared guidelines of FITC/SFNDT].
Victor Gueutin, Stéphane Dalle, Corinne Isnard-Bagnis, Ariane Laparra, Souad Assad

Bull Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Alizée Bozonnat, Marie Beylot-Barry, Olivier Dereure, Michel D'Incan, Gaëlle Quereux, Stephane Dalle

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When to stop immunotherapy for advanced melanoma: the emulated target trials.
Mathilde Amiot, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sophie Dalac

EClinicalMedicine· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis